EWTX News and Press, Edgewise Therapeutics Inc. From 06/26/23

– Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history – – Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers associated with skeletal muscl...

2023-06-16 17:39:00 ET Gainers: Kezar Life Sciences ( NASDAQ: KZR ) +6% . Telos Corporation ( TLS ) +4% . Dyne Therapeutics ( DYN ) +4% . Recursion Pharmaceuticals ( RXRX ) +4% . Berry Corporation ( BRY ) +4% . Losers: ...

2023-06-13 04:32:53 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased to $21.31B in Q1 2023, with Visa, McKesson, UnitedHealth, Elevance Health, and General Electric as the largest holdings. New stakes were established in Lululemon Athletica, Sherwin-Williams,...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, announced today that management will present at the Goldman Sachs Global Healthc...

2023-05-11 11:44:17 ET Edgewise Therapeutics press release ( NASDAQ: EWTX ): Q1 GAAP EPS of -$0.36. Cash, cash equivalents and marketable securities of $328 million as of March 31, 2023 For further details see: Edgewise Therapeutics GAAP EPS of -$0.36

– Advancing Phase 2 trials of EDG-5506 in Becker muscular dystrophy (BMD, CANYON ) and Duchenne muscular dystrophy (DMD, LYNX) – – Advancing exercise challenge study of EDG-5506 in Limb girdle muscular dystrophy 2I, BMD and McArdle Disease (LGMD2...

2023-05-01 12:51:17 ET Edgewise Therapeutics ( NASDAQ: EWTX ) added ~14% on Monday to reach the highest level in more than two months after Truist launched its coverage with a Buy rating and a $25 per share target, citing the prospects of its lead candidate EDG-5506. Citing ...

- Data provide key insights supporting Edgewise’s strategy to advance EDG-5506 for the treatment of Duchenne and Becker muscular dystrophy - Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the virtual Stifel 2023 CNS Days...

– Podium presentation on March 22, 2023 – – Company to host an Industry Forum to discuss its new approach to protecting dystrophic muscle featuring a key opinion leader – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceu...